In one phase I of two clinical trials, significant decrease in the p-Src expression on epidermal keratinocytes on sequential skin biopsies occurred using the Src kinase inhibitor dasatinib with trastuzumab, and paclitaxel as first-line therapy for patients with HER2 over-expressing advanced breast cancer [112]. This evidence concerns the gene ERBB2 and breast carcinoma.